Immunologic Monitoring and Cellular Products Laboratory

翻译后摘要：免疫监测和细胞产品实验室（IMCPL） IMCPL开发新的程序和测定，以支持治疗性免疫治疗产品的产生， 血液和组织库，以及UPCI癌症患者的免疫监测。具体目标 IMCPL的主要任务是：1）处理来自参与研究的患者的血液和组织，并储存生物标本， IMCPL相关的临床方案; 2）促进临床前开发，放大和制备高质量的 用于癌症的细胞、病毒和基因治疗的产品;以及3）提供对一系列 参与UPCI临床试验和研究方案的患者的免疫功能。IMCPL 共享资源由三项服务组成，包括：a）组织采购设施（TPF）： TPF为参与的患者提供专门的血液和组织处理以及银行服务， 临床方案。能力包括速冻、OCT或福尔马林处理和单细胞消化， TIL分离用于立即分析或建库; B）细胞产物实验室（CPL）：CPL是 致力于临床前开发，放大和制备高质量的细胞和基因产品 治疗癌症。这包括自体细胞和细胞系，体外修饰的组织或血细胞， 过继转移，和由肽、蛋白质和细胞制备的疫苗，以及临床级病毒 免疫监测实验室（IML）：IML负责连续监测 参与UPCI临床试验和研究方案的患者的一系列免疫功能。 该实验室提供最先进的纵向免疫监测与QA/QC，以及对测试的建议 选择和结果解释。总之，IMCPL是一个独特的实验室，支持研究人员， UPCI追求细胞疗法，病毒产品和免疫调节，其研究利用外周血淋巴细胞， 临床试验病人的血液和组织服务由训练有素的人员提供， 独立QA监督的实验室。IMCPL使UPCI研究人员和临床医生能够执行 基于自体和同种异体细胞的临床试验，以获得特殊处理的血液和肿瘤 样本，并研究患者的广泛免疫功能。IMCPL工作人员彻底 以标准化和有质量保证的方式进行培训和运作。在本项目期间 所有10个UPCI研究项目的研究者都使用了IMCPL。

Abstract: Immunologic Monitoring and Cellular Products Laboratory (IMCPL) IMCPL develops novel procedures and assays to support therapeutic immunotherapy product generation, blood and tissue banking, and immunologic monitoring of patients with cancer at the UPCI. The specific aims of IMCPL are to: 1) Process blood and tissue and bank biologic specimens from patients participating in IMCPL-related clinical protocols; 2) Facilitate preclinical development, scale-up and preparation of high quality products for cellular, viral and gene therapy of cancer; and 3) Provide serial monitoring of an array of immunologic functions in patients who participate in clinical trials and research protocols at the UPCI. The IMCPL Shared Resource is comprised of three services that include the: a) Tissue Procurement Facility (TPF): The TPF provides specialized blood and tissue processing and banking services for patients participating in clinical protocols. Capabilities include snap freezing, OCT or formalin treatment and single cell digestion and TIL isolation for immediate analysis or banking; b) Cellular Products Laboratory (CPL): The CPL is dedicated to preclinical development, scale-up and preparation of high quality products for cellular and gene therapy of cancer. This includes autologous cells and cell lines, tissue or blood cells modified in vitro for adoptive transfer, and vaccines prepared from peptides, proteins and cells, as well as clinical grade viral vectors; and c) Immunologic Monitoring Laboratory (IML): The IML has responsibility for serial monitoring of an array of immunologic functions in patients who participate in clinical trials and research protocols at the UPCI. The laboratory provides state-of-the-art longitudinal immunologic monitoring with QA/QC, as well as advice on test selection and result interpretation. Together, the IMCPL is a unique laboratory which supports the investigators of the UPCI pursuing cellular therapies, viral products and immune modulation and whose research utilize peripheral blood and tissue from patients on clinical trials. Services are provided by well trained personnel in a certified laboratory with independent QA oversight. The IMCPL enables UPCI researchers and clinicians to perform clinical trials based on autologous and allogeneic cells, to obtain specially processed blood and tumor samples, and to investigate a wide array of immune functions in patients. The IMCPL staff is thoroughly trained and operates in a standardized and quality-assured fashion. During the current project period investigators in all 10 UPCI Research Programs used the IMCPL.